NCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
Clinical Trials
46 trialsNCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT01445509 2026-01-15
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03148418 2026-01-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05112965 2026-01-07
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT06311851 2025-11-25
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Pardis Noor Medical Imaging and Cancer Center
Phase 1/2 Recruiting
NCT01187199 2025-10-27
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06796907 2025-10-14
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT01061515 2025-09-17
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT02420509 2025-06-04
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
Terminated
NCT06031233 2025-05-21
MINUTE
Isala
Phase 4 Recruiting
NCT06232902 2024-12-18
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
Qilu Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT01015222 2022-11-23
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01588184 2020-11-05
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Hoffmann-La Roche
Phase 4 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01514123 2020-09-17
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
Circadian Technologies Ltd.
Phase 1 Completed
NCT00095459 2019-12-17
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01251926 2019-11-15
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01898130 2019-09-17
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Northwestern University
Phase 2 Completed
NCT00761644 2019-04-11
Doxil, Bevacizumab and Temsirolimus Trial
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01274624 2018-12-19
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
Phase 1 Completed
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT02640365 2017-01-31
DOUBLIRI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 1 Completed
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00177307 2016-07-12
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
University of Pittsburgh
Phase 2 Completed
NCT00809133 2016-03-14
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00222729 2016-02-15
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT00740168 2016-01-21
BevaRet
Technische Universität Dresden
Completed
NCT00585377 2015-09-24
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
University of Utah
Phase 2 Completed
NCT00458315 2015-05-08
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Phase 2 Withdrawn
NCT00448136 2015-01-22
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Hoffmann-La Roche
Phase 2 Completed
NCT00710268 2015-01-14
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01193595 2014-12-03
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT02031991 2014-08-15
A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)
Pfizer
Phase 1 Completed
NCT00667485 2014-01-17
Rapamycin Plus Bevacizumab in Advanced Cancers
University of Chicago
Phase 1 Completed
NCT00360360 2013-12-04
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00109057 2013-06-21
An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT00597506 2012-12-27
BEV/EV
Duke University
Phase 2 Completed
NCT00226005 2012-05-09
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer Research Team
Phase 2 Completed
NCT00395434 2011-10-31
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
Mateon Therapeutics
Phase 1 Completed
NCT01271166 2011-01-06
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
Novartis
Phase 1 Terminated
NCT00611793 2009-01-23
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed